Early in November in the USA thoughts not just turn to elections but also to Kidney Week. The American Society of Nephrologists Kidney Week is the biggest event in the renal conference year.
There are huge amount of presentations , posters and publications. Over 3000 abstracts about all things kidney can be seen. They are held in a database for anyone to see. If printed out there would be over a 1000 pages.
But the data base can be filtered and a search for “aHUS” produces 22 which are relevant.
A link to each of those abstracts is given below sorted, according to the topics in the Global aHUS Patients’ Research Agenda. (note that the links will continue until ASN remove Kidney Week abstracts from its website)
Causes: Genetics and triggers
COVID-19 Vaccination as a Trigger for Atypical Hemolytic Uremic Syndrome
Characterization of Patients With Thrombotic Microangiopathy and Triggering/Associated Events: A Global aHUS Registry Analysis
Early Pregnancy-Associated Atypical Hemolytic Uremic Syndrome (aHUS)
Pregnancy-Associated Hemolytic Uremic Syndrome: Two Case Series From the University of Vermont Medical Center
Pancreatitis-Associated Atypical Hemolytic Uremic Syndrome
Thrombotic Microangiopathy (TMA) After Kidney Transplant: A 10-Year Experience
Atypical Hemolytic Uremic Syndrome due to Factor H Antibodies Following COVID-19
Recurrent Hemolysis in a Child With Shiga Toxin-Producing Escherichia coli and Two Heterozygous Variants Associated With Atypical Hemolytic Uremic Syndrome
Thrombotic Microangiopathy Associated With Use of Liposomal Doxorubicin
Revealing Complement Regulatory Functions of Thrombospondin-1 as New Potential Mechanism in Renal Disease
PLASMIC Score to Aid Diagnosis of Atypical Hemolytic Uremic Syndrome: A Post Hoc Analysis of Data From C5 Inhibitor Trials
Identifying the Etiology of Thrombotic Microangiopathy (TMA) Diagnosed by Kidney Biopsy Using Machine Learning Tools (Unsupervised Clustering)
Severe Postpartum HELLP Syndrome: Is This Atypical Hemolytic Uremic Syndrome?
COVID-19 Mimicking Classic Hemolytic Syndrome in a Toddler
Two Phase 3 Trials Evaluating Crovalimab in Patients With Atypical Haemolytic Uraemic Syndrome (aHUS): COMMUTE-a and COMMUTE-p
Outcome of Atypical Hemolytic Uremic Syndrome (aHUS) Treated With C5-Inhibition, Primary vs. Secondary vs. Idiopathic: Results From the ItalKid-HUS Network
Long-Term Outcomes in Eculizumab-Treated Patients Enrolled in the Global aHUS Registry
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study
Obinutuzumab Induction in a Kidney Transplant Recipient With Atypical Hemolytic Uremic Syndrome due to CFHR1/CFHR3 Gene Mutation and Anti-Complement Factor H Antibody
Diarrheal Dilemma: A Unique Cause of Atypical Hemolytic Uremic Syndrome
A Case of Mutation Negative Transplant Associated Thrombotic Microangiopathy Successfully Treated With Eculizumab
Impact : Clinical/Psychological
Desires and Needs of Dutch Atypical Hemolytic Uremic Syndrome Patients and Relatives
Impact : Socio – Economic
Article No: 548